Xadago

(Safinamide)

Xadago

Drug updated on 11/14/2023

Dosage FormTablet (oral: 50 mg, 100 mg)
Drug ClassMonoamine oxidase type B (MAO-B) inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.